Celdara Medical (OnCyte) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Financing Rounds
  • 1

Celdara Medical (OnCyte) General Information

Description

Developer of treatments in the field of immuno-oncology. The business unit has developed the most advanced autologous CAR (chimeric antigen receptor) T-Cell drug candidate uses a specific human Natural Killer cell receptor that targets tumor antigens expressed in most liquid and solid cancers.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Acquirer
Celyad Oncology
Primary Office
  • Lebanon, NH
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Celdara Medical (OnCyte) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Celdara Medical (OnCyte)‘s full profile, request access.

Request a free trial

Celdara Medical (OnCyte) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Celdara Medical (OnCyte)‘s full profile, request access.

Request a free trial